![]() |
市場調查報告書
商品編碼
1487659
外用抗生素市場 - 按藥物類別、劑型、產品類型、藥物類型、應用、配銷通路、全球預測 2024 - 2032 年Topical Antibiotics Market - By Drug Class, Dosage Form, Product Type, Medication Type, Application, Distribution Channel, Global Forecast 2024 - 2032 |
由於細菌和真菌感染等皮膚感染盛行率不斷上升,預計 2024 年至 2032 年外用抗生素市場規模的複合年成長率將達到 5.4%。糖尿病足潰瘍和壓瘡等慢性傷口的發生率不斷上升,促使人們採用外用抗生素來治療傷口和預防感染。根據著名醫學雜誌《JAMA》報道,每年,糖尿病足潰瘍影響全球約1860 萬人,其中約160 萬例發生在美國。將刺激人們對感染控制措施的重視。
製造商正在進一步開發創新配方,例如霜劑、軟膏、凝膠和噴霧劑,以提高滲透性和持續釋放特性,以最佳化藥物傳輸並提高患者依從性。美容皮膚科擴大採用外用抗生素來治療痤瘡和其他皮膚病,加上消費者對非處方外用抗生素產品的需求不斷成長,將有助於市場的擴張。
外用抗生素產業分為藥品類別、劑型、產品類型、用藥類型、應用、配銷通路和地區。
到 2032 年,學名藥產品類型細分市場的市場規模預計將實現 5.9% 的複合年成長率。通用外用抗生素的可近性和可負擔性使其對醫療保健提供者和患者更具吸引力。學名藥製造商也投資研發活動,以創造生物等效製劑,以確保與品牌製劑具有可比性的功效和安全性。
眼部感染應用領域的局部抗生素市佔率預計在 2024 年至 2032 年期間將成長 5.5%。眼部感染,例如結膜炎和角膜炎,是由細菌或真菌病原體引起的常見眼部疾病,需要及時有效地使用局部抗生素進行治療。與不良衛生習慣、隱形眼鏡使用和環境因素相關的眼部感染盛行率不斷上升,將增加對局部抗生素作為主要治療介入的需求。
由於人口密度高和熱帶氣候為細菌和真菌感染的傳播創造了有利的環境,預計到 2032 年,亞太地區外用抗生素產業將獲得動力並以 5.8% 的複合年成長率成長。在亞太地區人口稠密的城市地區和農村社區,結膜炎、膿皰病和皮膚真菌感染等傳染病的發生率正在增加。中國、印度和東南亞國家等國家不斷擴大的醫療基礎設施和不斷成長的可支配收入將推動外用抗生素的可及性,進一步推動區域市場的擴張。
Topical antibiotics market size is predicted to witness 5.4% CAGR from 2024 to 2032, driven by the increasing prevalence of skin infections, including bacterial and fungal infections. The rising incidence of chronic wounds, such as diabetic foot ulcers and pressure ulcers is driving the adoption of topical antibiotics for wound management and infection prevention. As per well-known medical journal JAMA, every year, diabetic foot ulcers impact roughly 18.6 million individuals globally, with approximately 1.6 million cases occurring in the U.S. The growing awareness about the importance of infection control measures, particularly in healthcare settings, will stimulate the demand for topical antibiotics for the treatment and prevention of healthcare-associated infections.
Manufacturers are further developing innovative formulations, such as creams, ointments, gels, and sprays, with improved penetration and sustained release properties for optimizing drug delivery and enhancing patient compliance. The increasing adoption of topical antibiotics in cosmetic dermatology for the treatment of acne and other skin conditions, coupled with the rising consumer demand for OTC topical antibiotic products will contribute to the market expansion.
The topical antibiotics industry is divided into drug class, dosage form, product type, medication type, application, distribution channel, and region.
The market size from the generics product type segment is set to witness 5.9% CAGR up to 2032. As patents for branded topical antibiotics expire, generic versions have become available, leading to increased competition and lower prices. This accessibility and affordability of generic topical antibiotics makes them more attractive to healthcare providers and patients. Generic manufacturers are also investing in R&D activities to create bioequivalent formulations for ensuring comparable efficacy and safety to their branded counterparts.
Topical antibiotics market share from the eye infection application segment is anticipated to observe 5.5% growth rate during 2024-2032. Eye infections, such as conjunctivitis and keratitis, are common ocular conditions caused by bacterial or fungal pathogens, necessitating prompt and effective treatment with topical antibiotics. The increasing prevalence of eye infections, associated to poor hygiene practices, contact lens use, and environmental factors will contribute to the demand for topical antibiotics as the primary therapeutic intervention.
Asia Pacific topical antibiotics industry is anticipated to gain momentum and grow at a 5.8% CAGR through 2032, attributed to the high population density and tropical climate that creates conducive environments for the spread of bacterial and fungal infections. The incidence of infectious diseases, such as conjunctivitis, impetigo, and fungal skin infections, in densely populated urban areas and rural communities across APAC is increasing. The expanding healthcare infrastructure and the rising disposable incomes in countries like China, India, and Southeast Asian nations will fuel the accessibility of topical antibiotics, further driving the regional market expansion.